Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:55:45.511Z.
Consensus retrieved: 2026-10-06T09:44:43.409Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:55:45.511Z.
Quote observation: 2026-10-06T15:47:28.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4b47dc168d162d1a8799ce58e4fab29ef684c29fe4f2d0edb18e5266ad2cbc09
Forward PE Ratio (N/A) = Dated Quote Price ($1.14) / Consensus Forward EPS ($0.03)
FORWARD PE RATIO
N/A
biote Corp.
Market Cap
$50.28M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| biote Corp. (BTMD) | $50.28M | N/A |
| Celularity Inc. (CELU)vs › | $49.93M | N/A |
| Apollomics, Inc. (APLM)vs › | $49.87M | N/A |
| Microbot Medical Inc. (MBOT)vs › | $50.81M | N/A |
| Clene Inc. (CLNN)vs › | $51.09M | N/A |
| INmune Bio, Inc. (INMB)vs › | $51.18M | N/A |
| Envoy Medical, Inc. (COCH)vs › | $51.34M | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.36M | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.54M | N/A |
Trailing P/E
9.8
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.03 implies -75.0% EPS decline vs the reported trailing $0.12.
At the dated quote price of $1.14, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.03 | $0.02 – $0.03 | 1 | 41.5x |
| 2027-12-31 | $0.24 | $0.13 – $0.35 | 1 | 4.8x |
| 2028-12-31 | $0.50 | $0.49 – $0.51 | 1 | 2.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
